{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-013486","form_type":"8-K","ticker":"PASG","cik":"0001787297","company_name":"Passage BIO, Inc.","filed_at":"2023-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.240497+00:00","generated_at":"2026-06-12T04:37:18.464309+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Passage Bio Q2 net loss $23.9M; GM1 gene therapy shows biomarker normalization at Dose 2; cash runway extended","bullets":["Net loss $23.9M ($0.44/sh) vs $39.5M ($0.73) in Q2 2022.","Cash and marketable securities $151.5M; cash runway extended into Q4 2025 after restructuring.","Interim GM1 data: PBGM01 well-tolerated; Dose 2 achieved normal CSF β-Gal activity and GM1 ganglioside levels durable to 12mo.","First patient dosed at Dose 3 in July 2023; initial safety/biomarker data expected by mid-2024.","FTD trial PBFT02: initial Cohort 1 data expected Q4 2023; six sites initiated in Brazil, Canada, US."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-013486","json":"https://secwatch.observer/filing/0001558370-23-013486.json","markdown":"https://secwatch.observer/filing/0001558370-23-013486.md","text":"https://secwatch.observer/filing/0001558370-23-013486.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787297/000155837023013486/0001558370-23-013486-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787297/000155837023013486/pasg-20230807x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T04:37:18.464309+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a4f646e5ca0e29d8ddbafb42809e6ef8e9273c5d","claim":"Passage BIO, Inc. reported the second quarter ended June 30, 2023 results: net income Net loss was $23.9 million, or a net loss of $0.44 per basic and diluted share, EPS $0.44 per basic and diluted share.","evidence_excerpt":"Net loss was $23.9 million, or a net loss of $0.44 per basic and diluted share, for the quarter ended June 30, 2023, compared to $39.5 million, or a net loss of $0.73 per basic and diluted share, for the same quarter in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787297/000155837023013486/0001558370-23-013486-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss was $23.9 million, or a net loss of $0.44 per basic and diluted share"},{"label":"EPS","value":"$0.44 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}